Journal • Mismatch repair • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden)
|
KRAS mutation • HER-2 expression • KRAS wild-type • RAS wild-type • PD-L1 expression + HER-2 overexpression
|
Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium